The Limited Times

Now you can see non-English news...

Not only a slowdown, but also an improvement: encouraging results from an experiment in innovative treatment for multiple sclerosis - Walla! news

2020-12-13T13:42:17.576Z


Neurogenesis is developing stem cell use against degenerative diseases. The findings of Phase 2 of an experiment she conducted with Hadassah Medical Center, in which patients received NG-01 cells from the bone marrow, showed that patients in the advanced stage of the disease improved their motor and cognitive abilities. "Hints at potential"


  • news

Not only slowing down, but also improving: encouraging results from experimenting with innovative treatment for multiple sclerosis

Neurogenesis is developing stem cell use against degenerative diseases.

The findings of Phase 2 of an experiment she conducted with Hadassah Medical Center, in which patients received NG-01 cells from the bone marrow, showed that patients in the advanced stage of the disease improved their motor and cognitive abilities.

"Hints at potential"

Tags

  • Multiple Sclerosis

  • Experiments

  • trial

  • Hadassah

Meirav Cohen

Saturday, December 12, 2020, 2:30 p.m.

  • Share on Facebook

  • Share on WhatsApp

  • Share on general

  • Share on general

  • Share on Twitter

  • Share on Email

0 comments

  • Floods in the south of the country due to the weather 05.12.20

  • Trump: "We have achieved a medical miracle - Pfizer's vaccine approved ...

  • The entrance to the city of Arad 09.12.20

  • Simulation exercise of the arrival of vaccines.

    Sheba Hospital, Tel ...

  • Saar resigned from the Knesset: "Establishes a large political force that will replace ...

  • Murder in the streets: A 50-year-old woman was stabbed to death, her son arrested

  • With Israeli UAVs and Erdogan: Azerbaijan celebrated ...

  • Netanyahu on the agreement with Morocco: "This is a great light for Israel ...

  • Two children were fatally injured in a car accident near the gate ...

  • The dream and broke: the corona stopped the hospitality project "De ...

In the video: Starting in Israel The clinical trial phase of the corona vaccine - Netanyahu Ganz and Edelstein refer to the trial (Photo: GPO)

An innovative trial designed to treat multiple sclerosis has been found to be effective, and as one that improves the condition of patients, and not only slows the intensity of the disease, according to the results of a recent trial conducted by Neurogenesis in collaboration with Hadassah Medical Center.

The results of the second phase of the trial indicate a possible chance for effective treatment of progressive multiple sclerosis - the more severe form of the disease.

The treatment is carried out by inserting stem cells into the patient's body, and is designed to fight degenerative diseases of the nervous system to fight his disease.



"In many cases, the patients' improvement was impressive and included restoration of motor activity and a clear impact on their cognitive abilities," said Prof. Dimitrios Crossis, principal investigator of the experiment and director of the Multiple Sclerosis Center and the Neuroimmunology Unit at Hadassah Medical Center.

"The treatment was well tolerated and the clinical trial met all the main objectives," he said.



In the experiment, Prof. Dimitrios Crucius, Dr. Petro Panayota and Dr. Ibrahim Cassis examined the effect of NG-01 - a unique subpopulation of self-derived mesenchymal stem cells from bone marrow - on patients with progressive multiple sclerosis.

More on Walla!

NEWS

  • Emirates on Chinese vaccine for corona: "86% effective"

  • The safety data of the Pfizer vaccine have been published.

    Common side effects: fever and weakness

  • Modern has formally applied for US vaccine approval: "94.1% efficacy"

  • Are you buying car insurance?

    This is how you will do it right

Innovative method, encouraging results.

Stem cells (Photo: GettyImages)

Neurogenesis is a biopharmaceutical company in the clinical development stages that deals with innovative treatments in stem cells against degenerative diseases of the nervous system, and the experiment was conducted in collaboration with Hadassah Medical Center.

The impressive results announced are from the second phase of the controlled clinical trial.

They were recently published in Brain, a prestigious scientific journal of the University of Oxford, and were even selected as "Editor's Choice" - showing that the treatment was safe to use and without significant side effects.



Two main target metrics were set for the experiment.

The first is the safety of injection of NG-01 cells into the spinal canal or vein.

It is measured through the prevalence of side effects relative to the placebo group.

The second measure is the differences between the three participating groups - to estimate the level of disability of MS patients - and the proportion of patients whose treatment failed.



According to the findings, the treatment by injection into the spinal canal or intravenous injection led to a significant decrease in the number of cases of disease progression relative to the control group that received placebo treatment: 6.7% and 9.7% compared to 41.9%, respectively.

In 58% of patients treated with NG-01 injection into the spinal canal, there was no evidence of active disease throughout the treatment period, compared with 9.7% in the placebo group.

Also, the NG-01 treatment groups showed a significant improvement in walking ability.

More on Walla!

NEWS

This disease affects everyone else, but there is something to be done

To the full article

"Although we currently have a number of good treatment options for relapsing-remitting multiple sclerosis, there is no effective response that can significantly delay the progression of the disease in progressive multiple sclerosis," Crossis added.

"This trial provides encouraging results and hints at the potential of a new approach that can not only slow disease progression but also improve and advance the mechanisms of progressive multiple sclerosis."



Multiple sclerosis (MS) is an autoimmune disease that causes damage to the myelin sheath and nerve cells of the central nervous system (foci of myelin damage to the brain and spinal cord), resulting in cumulative neurological disability.

Destruction of myelin (the shell that protects nerve cell extensions and allows efficient transmission of nerve signals), causes secondary damage to nerve cells and gradual degeneration.

The disease often causes sensory disturbances in the limbs, including tingling or stinging sensations, numbness, pain or itching.

Motor problems are soon common in sclerosis patients, who may suffer from tremor, stiff muscles, excessive reflexes, weakness or paralysis of the limb muscles, difficulty walking and poor control of the braces.



In addition, the disease also involves vision problems, such as blurred or double vision, or partial or complete vision loss.

The disease cannot be cured, and current treatments are primarily designed to reduce seizures and slow the rate of nerve damage.

  • Share on Facebook

  • Share on WhatsApp

  • Share on general

  • Share on general

  • Share on Twitter

  • Share on Email

0 comments

Source: walla

All news articles on 2020-12-13

You may like

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.